One study showed that LPS-treated APP/PS1 transgenic mice had decreased TREM2 levels and increased TLR4 levels, indicating that TLR4/TREM2 may be a potential link between AD and systemic inflammation and TREM2 can serve as a potential therapeutic target for treating systemic inflammation in AD [29]. This evidence concerns the gene TLR4 and Alzheimer disease.